Partially — you are right about magnitude, but wrong to distrust direction. The legacy extraction of the target paper supplies consistent qualitative directions across ten measured variables: LPS increases NAD⁺, cADPR, CD38, intracellular Ca²⁺, iNOS/NO, and TNF-α/IL-1β/IL-6, while CD38Ri or 8-Br-cADPR reduces these in the LPS context . Concordant, multi-endpoint directions justify moderate confidence in the sign of effects even without raw numbers. What is genuinely uncertain — and where your caution is warranted — is effect size, variability, and statistical strength, since no replicate values, error bars, or p-values survive the legacy extraction.
Figure note: This plots only the reported direction of each effect from the legacy extraction — a categorical summary, not quantitative data. Red = pathway up (LPS-stimulated); blue = pathway down (CD38Ri or 8-Br-cADPR relative to LPS). No numeric magnitudes are available in the provided record, so this is the most honest visualization possible.
Sufficient for inference: sign/direction consistency across biochemical (NAD⁺, cADPR, Ca²⁺), effector (NO, cytokines), and cell-fate (apoptosis) endpoints, using two independent perturbations (genetic CD38Ri + pharmacologic 8-Br-cADPR) .
Insufficient (legitimately uncertain): replicate-level numbers, exact fold-changes, p-values, and figure panels. The legacy extraction schema (not the paper itself) is the bottleneck — the full text likely contains these, but they were not preserved in the structured record .
Do not discount the causal direction — concordance across 10 variables and 2 perturbation modalities is strong triangulation. Do suspend judgment on magnitude, dose-dependence, and statistical significance until you either (a) access the full text directly, or (b) run a focused extraction on the original figures. Your instinct is calibrated for effect size, not for direction.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.